# NCT07085728 (NCT07085728)

> Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07085728
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Eastern Cooperative Oncology Group
- Conditions: Myeloma Multiple
- Interventions: Cyclophosphamide; Bortezomib (VELCADE); Dexamethasone; Daratumumab-hyaluronidase
- Enrollment: 74
- Primary outcome: Renal Response Rate

## Commentary we found

- X threads: 41

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct07085728

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07085728", "email": "<work email>"}; the inbox owner confirms by the emailed link.